Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + pomalidomide + dexamethasone (Isa Pd) in previously treated AL amyloidosis without VGPR or better
2020-004333-20Phase 2Active
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, pomalidomide and dexamethasone in amyloidosis, sponsored by Inter-Groupe Francophone du Myélome. Primary endpoint: Primary hematologic response at end of cycle 6. Started Sep 2021; status: active.
02
Drugs
isatuximabpomalidomidedexamethasone
03
Conditions
amyloidosis
Beyond the preview
Go deeper on 2020-004333-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004333-20.